Miraculins Inc. announced that its PreVu Non-Invasive Skin Cholesterol Point of Care Test has now been CE Marked and is officially registered within the European Union. CE Marking allows the PreVu POC test to be marketed in the European Union for coronary artery disease risk assessment screening for use within the general population. CE marking confirms that the PreVu Non-Invasive Skin Cholesterol POC Test complies with the Essential Requirements of the European In Vitro Diagnostic Directive 98/79/EC, part of which includes the requirement to possess a certified Quality Management System. Miraculins was issued its formal ISO 13485 Certificate of Registration by The BSI Group Inc. on January 13, 2012.